| Literature DB >> 35448764 |
Umar M Badeggi1, Sylvester I Omoruyi1, Enas Ismail1,2, Charlene Africa3, Subelia Botha4, Ahmed A Hussein1.
Abstract
The reducing potential of plant extracts in the green synthesis of nanoparticles has been associated with their phytochemicals. Although pharmacologically inactive, a norlignan diglucoside "hypoxoside" (HP) occurs in large quantities in the extract of Hypoxis hemerocallidea (HE). In this work, HP was isolated from HE where both were used in the biosynthesis of the corresponding silver nanoparticles (HP-AgNPs and HE-AgNPs). The AgNPs were fully characterized using various physicochemical techniques and their antimicrobial and anticancer properties were evaluated. Transmission electron microscopy (TEM) revealed sizes of 24.3 ± 4 nm for the HE-AgNPs and 3.9 ± 1.6 nm for the HP-AgNPs. The HE-AgNPs demonstrated enhanced anti-bactericidal effects on Escherichia coli and Salmonella enterica with a minimum inhibitory concentration (MIC) value of 1.95 µg/mL, competing well with the standard drug. The cytotoxic activity showed that the HE-AgNPs reduced cell viability with an IC50 of 0.81 and 4.0 µg/mL, respectively, for the U87 and U251 cells, while the HP-AgNPs displayed 0.20 and 0.55 µg/mL for both cell lines, respectively. Furthermore, while the HE-AgNPs were selective to U87 alone, the HP-AgNPs were selective to both glioblastoma cells tested. The study demonstrated the ability of a single phytoconstituent (hypoxoside), not only as the chief bioreductant in the extract, but also as a standalone reducing and capping agent, producing ultra-small, spherical, and monodispersed AgNPs with enhanced biological properties.Entities:
Keywords: Hypoxis hemerocallidea; antimicrobial; characterization; cytotoxicity; glioblastoma cells; hypoxoside; silver nanoparticles
Year: 2022 PMID: 35448764 PMCID: PMC9033108 DOI: 10.3390/plants11081037
Source DB: PubMed Journal: Plants (Basel) ISSN: 2223-7747
Figure 1Structure of hypoxoside (A) and rooperol (B) upon conversion using β-glucosidase enzyme and hypoxoside/AgNPs conjugate (C).
Figure 2UV-Vis spectra of HE-AgNPs (a) and HP-AgNPs (b). The insets (i) and (ii) represent the colour of the HE-AgNPs and HP-AgNPs, respectively.
Figure 3High-resolution transmission electron microscopy images showing the morphology of (A,C) HE-AgNPs and (B,D) HP-AgNPs. (E,F) are histograms displaying the particle size distribution of HE-AgNPs and HP-AgNPs, respectively.
HE-AgNPs consist of various shapes with spheres dominating.
| Nanoparticles | Shape Distribution (%) | ||
|---|---|---|---|
| Oval | Cone | Cylinder | |
| HE-AgNPs | 84.01 | 0.93 | 15.06 |
Figure 4XRD patterns showing the diffraction peaks of HE-AgNPs (A) and HP-AgNPs (B). A selected area electron diffraction of HE-AgNPs (C) and HP-AgNPs (D) represented their crystallinity degree.
Figure 5Hydrodynamic size (HDS) and polydispersity index (PDI) showing the population of particles in (A) HE-AgNPs and (B) HP-AgNPs.
Figure 6Zeta potential of (A) HE-AgNPs and (B) HP-AgNPs indicating that the surfaces of the nanoparticles are surrounded by negative ions.
MIC values of the antimicrobial activities of AgNPs and the standard in µg/mL.
| Antimicrobial Activities of Silver Nanoparticles | |||
|---|---|---|---|
| Bacteria Species | HE-AgNPs | HP-AgNPs | CTD |
|
| 125.00 | 125.00 | 1.95 |
|
| 62.50 | 31.35 | 1.95 |
|
| 125.00 | 1.95 ** | 1.95 |
|
| 125.00 | 125.00 | 1.95 |
|
| 31.25 | 1.95 ** | 1.95 |
|
| 62.50 | 62.50 | 1.95 |
CTD: Ceftazidime, HE-AgNPs: Hypoxis hemerocallidea extract-mediated silver nanoparticles, HP-AgNPs: hypoxoside-mediated silver nanoparticles. **: MIC values equal to those of the standard drug used.
Figure 7Cytotoxicity of HE-AgNPs (A) and HP-AgNPs (B) on the U251, U87, and HaCaT cell lines as obtained from MTT assays.
IC50 values and selectivity index (SI) of AgNPs.
| NPs Samples | Test Items | U87 | U251 | HaCaT |
|---|---|---|---|---|
| (µg/mL) | (µg/mL) | (µg/mL) | ||
| HE-AgNPs | IC50 | 0.81 | 4.0 | 3.67 |
| SI | 4.53 | 0.92 | ||
| HP-AgNPs | IC50 | 0.20 | 0.55 | 1.97 |
| SI | 9.85 | 3.58 |